Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to ,9 Years of Age

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

(2011) Adriano Arguedas et al.   Human vaccines & immunotherapeutics

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial

(2011) Eric Plennevaux et al.   VACCINE

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

(2011) Sara Meier et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities

(2010) Mark Loeb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to

(2010) Chi-Eun Oh et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial

(2009) Xiao-Feng Liang et al.   LANCET

A Novel Influenza A (H1N1) Vaccine in Various Age Groups

(2009) Feng-Cai Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009

(2009) Seema Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age

(2009) Adriano Arguedas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Optimizing Influenza Vaccine Distribution

(2009) J. Medlock et al.   SCIENCE

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy

(2009) Susanna Esposito et al.   VACCINE

Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems

(2008) Jan Bonhoeffer et al.   VACCINE